Cipla Limited — Important, 17-04-2025: Updates

Cipla's manufacturing facility of Medispray in Kundaim, Goa, was recently inspected by the USFDA from January 14 to 20, 2025, and has been classified as Voluntary Action Indicated (VAI). While this classification does not indicate any significant issues, it remains part of the company’s commitment to transparent governance. The communication from the USFDA was received on April 17, 2025. Investors should monitor this development closely, as it signifies the regulatory climate surrounding the facility, but at this stage, no immediate concerns have been highlighted.